CV Therapeutics At A Glance

Vision

CV Therapeutics was founded with a single focus—to discover, develop, and commercialize better drugs to help the millions of patients who have cardiovascular disease.

Company Overview

Founded more than 15 years ago by chairman and CEO Louis Lange, MD, PhD, CV Therapeutics is a biopharmaceutical company focused on applying molecular cardiology to discovering, developing, and commercializing novel, small molecule drugs for the treatment of cardiovascular disease—the number one cause of death in the United States. The cardiologists, clinicians, and researchers at CV Therapeutics work together to link the scientific discovery process with the real-world needs of patients with heart disease.

The company focuses on the biomedical discipline of molecular cardiology which applies advances in molecular biology and genetics to identify and delineate mechanisms of cardiovascular disease and new targets for drug discovery. By using novel, small molecules against these disease targets, CV Therapeutics is building a product portfolio that is intended to improve efficacy and/or reduce side effects compared with existing agents, creating new therapies for the treatment of patients suffering from cardiovascular conditions.

Product Portfolio

Ranexa^®: Ranexa (ranolazine extended-release tablets) is the first new pharmaceutical approach to treat chronic angina in the United States in more than 20 years. Complete safety and prescribing information can be found at www.Ranexa.com.

CV Therapeutics currently has multiple clinical and preclinical drug development programs and candidates. Learn more about our development pipeline.